<DOC>
	<DOCNO>NCT01898884</DOCNO>
	<brief_summary>The objective study : - To evaluate safety tolerability single multiple oral dos VP 20629 subject Friedreich 's ataxia ( FA ) . [ Primary ] - To characterize pharmacokinetics VP 20629 investigation plasma concentration-time profile follow single multiple oral dos subject FA . [ Secondary ] - To investigate pharmacodynamic effect VP 20629 plasma 8-isoprostane malondialdehyde urinary 8-hydroxydeoxyguanosine concentration follow multiple oral dos subject FA . [ Exploratory ]</brief_summary>
	<brief_title>Safety Pharmacology Study VP 20629 Adults With Friedreich 's Ataxia</brief_title>
	<detailed_description />
	<mesh_term>Ataxia</mesh_term>
	<mesh_term>Cerebellar Ataxia</mesh_term>
	<mesh_term>Friedreich Ataxia</mesh_term>
	<criteria>1 . Be 18 45 year age ( inclusive ) . 2 . Have body mass index 18 27 kg/m^2 ( inclusive ) . 3 . Have clinical presentation consistent FA . 4 . Have confirm diagnosis FA define expanded guanosine , adenine , adenine ( GAA ) triplet repeat number . 5 . Have International Cooperative Ataxia Rating Scale ( ICARS ) mean total score ≤75 . 6 . If female , postmenopausal ( cessation menses ≥1 year ) , surgically sterile , negative serum human chorionic gonadotropin pregnancy test within 5 day prior first dose study drug . Women child bear potential must also acceptable method birth control , determine Investigator , 3 month prior first dose must agree continue use 2 month last dose study drug . If male , surgically sterile agree follow acceptable method birth control determine Investigator , screen visit 2 month last dose study drug . 7 . Be able swallow capsule whole . 8 . Agree adhere protocoldefined schedule assessment procedure . 9 . Be inform nature study provide write informed consent studyspecific procedure perform . 1 . Have take coenzyme Q10 , idebenone , dietary herbal supplement ( antioxidative effect ) , overthecounter medication ( include homeopathic medicine vitamin ) within 1 week prior first dose study drug Day 1 . 2 . If female , pregnant breastfeeding . 3 . Have positive test result human immunodeficiency virus ( HIV ) , hepatitis B surface antigen , hepatitis C antibody . 4 . Have ingest alcohol within 48 hour admission clinical study unit Day 1 . NOTE : Caffeine intake limited 2 caffeinecontaining beverage per day time period . 5 . Have participate investigational drug trial within 30 day prior first dose study drug Day 1 . NOTE : Subjects receive study drug ( VP 20629 placebo ) singledose group study complete Posttreatment Safety Assessment allow enroll multipledose group follow 21 day washout period , provide continue meet protocol eligibility criterion . Subjects enroll multipledose group ongoing adverse event follow participation singledose group serious adverse event singledose group ( regardless causality ) . 6 . Have know hypersensitivity ingredient study formulation . 7 . Have , determine Investigator and/or medical monitor , clinically relevant medical surgical condition could interfere administration study drug , interpretation study result , compromise safety wellbeing subject . 8 . Have ColumbiaSuicide Severity Rating Scale ( CSSRS ) score 4 5 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>